For the purposes of this Regulation, the following definitions apply:
‘true positive’ means a specimen known to be positive for the target marker and correctly classified by the device;
‘false negative’ means a specimen known to be positive for the target marker and misclassified by the device;
‘false positive’ means a specimen known to be negative for the target marker and misclassified by the device;
‘the limit of detection’ (‘LOD’) means the smallest amount of the target marker that can be detected;
‘nucleic acid amplification techniques’ (‘NAT’) means methods of detection and/or quantification of nucleic acids by either amplification of a target sequence, by amplification of a signal or by hybridisation;
‘NAT system’ means the combination of devices used for extraction, amplification and detection of nucleic acids;
‘rapid test’ means a qualitative or semi-quantitative in vitro diagnostic medical device, used singly or in a small series, which involves non-automated procedures (except the reading of results) and has been designed to give a fast result;
‘robustness’ means the capacity of an analytical procedure to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability during normal usage;
‘cross-reactivity’ means the ability of non-target analytes or markers to cause false positive results in an assay because of similarity, e.g. the ability of non-specific antibodies binding to a test antigen of an antibody assay, or the ability of non-target nucleic acids to be reactive in a NAT assay;
‘interference’ means the ability of unrelated substances to affect the results in an assay;
‘whole system failure rate’ means the frequency of failures when the entire process is performed as prescribed by the manufacturer;
‘first-line assay’ means a device used to detect a marker or analyte, and the use of which may be followed by the use of a confirmatory assay; devices intended solely to be used to monitor a previously determined marker or analyte are not considered first-line assays;
‘confirmatory assay’ means a device used for the confirmation of a reactive result from a first line assay;
‘supplemental assay’ means a device that is used to provide further information for the interpretation of the test result of another assay;
‘virus typing device’ means a device used for typing with already known positive samples, not used for primary diagnosis of infection or for screening;
‘95 % positive cut-off value’ means the analyte concentration where 95 % of test runs give positive results following serial dilutions of an international reference material, where available, e.g. a World Health Organisation (WHO) International Standard or reference material calibrated against the WHO International Standard.